Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.

Brain cancer is the second-leading cause of death in children in the developed world. For the children who survive, standard ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

In February 2024, the government slashed GST (Goods and Services Tax) from three major cancer drugs: Trastuzumab Deruxtecan, ...

Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

retriever generates disease-specific transcriptional drug response signatures by merging transcriptional signatures over time, concentration, and cell-type. These signatures can then be matched to ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...